Drug Discovery World

SEPTEMBER 12, 2024

The money will support the continued pre-clinical development of the company’s two lead assets, Alfacyte and Dermacyte, as they move towards the clinic. Alfacyte is being developed for the treatment of upper respiratory tract infections and as a broad-spectrum antiviral.

Virus 147

Virus Engineering Clinical Development Drug Development 147

Drug Discovery World

JULY 26, 2023

A Cancer Research UK-funded clinical trial has shown, for the first time, that a new class of antibody could benefit cancer patients whose existing treatments have stopped working. The drug, MOv18 IgE, was developed by researchers at King’s College London.

Clinical Trials 130

Clinical Trials Immune Response Drugs Trials 130

Drug Target Review

SEPTEMBER 5, 2024

However, my goal was all the time to work with drug development in the pharma industry, so I moved on and started that journey in 1992 when I took on a role as Clinical Research Manager at AstraHässle, a mid-size Swedish pharma company. What potential future applications or implications do you foresee based on your work?

Pharma Companies 111

Pharma Companies Licensing Licensing Disease 111

Drug Discovery World

AUGUST 14, 2023

Research partners in the UK are progressing their orally available small molecule cancer immunotherapy drug into clinical development as a treatment for advanced solid tumours. We hope that this EP4-targeting approach will deliver a promising route to improving treatment options for patients with a broad range of cancers.”

Trials 130

Trials Small Molecule Pharmacokinetics Clinical Trials 130

Drug Discovery World

FEBRUARY 12, 2024

Cameron Ross, SVP, Generative AI, Elsevier “AI has the potential to dramatically shorten one of the most costly areas of early drug development – small molecule discovery. It’s no surprise that interest in AI for this area is surging, since early phase drug discovery normally accounts for 42% of the cost of the entire pipeline.

Small Molecule 349

Small Molecule Regulations Clinical Trials Therapies 349

Drug Discovery World

AUGUST 22, 2024

Prolonging health span with drug development Life Biosciences aims to restore and prolong a patient’s health span by targeting the underlying biology of ageing and increasing the quality of years one spends in good health compared with just increasing the total number of years one lives.

Therapies 147

Therapies DNA Disease RNA 147

Drug Discovery World

DECEMBER 27, 2023

Ng is working on critical challenges in clinical trials, specifically in planning and recruitment, and has been building innovative solutions designed to benefit patients and researchers – with a focus on efficiency, transparency and diversity in clinical development. Listen here. Listen here. Listen here. Listen here.

Targeted Protein Degradation 173

Targeted Protein Degradation Clinical Trials Pharma Companies Drug Development 173

Drug Discovery World

AUGUST 30, 2022

Emily Whitehead became the first child in the world to receive the revolutionary cell therapy treatment named CAR-T in 2012 as a last hope to cure her of leukaemia – she remains in remission 10 years later. Patient engagement during clinical development: keeping the “customer” in mind. Spotlight roundtables.

Therapies 246

Therapies Hospitals Clinical Trials Clinical Development 246

Drug Discovery World

OCTOBER 4, 2022

Oligomerix’s portfolio of compounds is expected to provide a potentially lower-cost treatment alternative and/or complement to the newly emerging high-cost therapeutic options such as the monoclonal antibody products. Diseases such as PSP and FTD have no licensed and available treatments. With its recent award of $3.35

Disease 130

Disease Small Molecule Compound Screening Clinical Development 130

Drug Target Review

AUGUST 28, 2024

What are the main challenges currently faced in the treatment of chronic liver diseases, and how does Resolution Therapeutics aim to address these challenges? Once a patient develops advanced cirrhosis/end-stage liver disease there are no specific therapies to significantly avoid major decompensations and death in the next few years.

Therapies 114

Therapies Disease Engineering Medical Schools 114

Drug Discovery World

FEBRUARY 10, 2023

The company’s global analysis of all clinical trials conducted in 2022 showed that Covid-19 came second. First-line AZ treatment for adults with biliary tract cancer approved The MHRA has approved Imfinzi in combination with gemcitabine and cisplatin as a first-line treatment for biliary tract cancer.

Clinical Trials 130

Clinical Trials Trials Drugs Vaccine 130

Drug Discovery World

NOVEMBER 22, 2022

Under the alliance agreement, Astex retains an exclusive worldwide licence to take the most promising projects forward into pre-clinical and clinical drug development. The post Academic-industry collaboration extends cancer drug discovery alliance appeared first on Drug Discovery World (DDW). ” .

Drugs 130

Drugs Engineering Clinical Development Research 130

Drug Target Review

FEBRUARY 1, 2024

What challenges has the industry faced in developing and commercialising treatments for neurological diseases, including rare diseases? But commitment to neuroscience drug development is critically important given the significant unmet medical needs and the ways in which patients, caregivers, and families suffer.

Therapies 104

Therapies Drug Development Disease Clinical Development 104

Drug Discovery World

MAY 3, 2023

Adcendo, a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of cancers with a high unmet medical need, has completed a successful Series A extension financing round, raising a further €31 million, following the €51 million Series A financing in April 2021.

Licensing 130

Licensing Licensing Clinical Development Therapies 130

Drug Discovery World

JULY 15, 2024

Dr Alexandra Sapetschnig, Group Leader at STORM Therapeutics, described the event as one that “really set the agenda for oncology research in 2024” through the display of new approaches and methods that are expanding opportunities in drug development. This bodes well for potential future research and therapies,” she adds.

Research 130

Research Clinical Pharmacology Therapies RNA 130

Drug Discovery World

NOVEMBER 9, 2023

DDW Editor Reece Armstrong speaks to Christian Leisner , Chief Executive Officer of antibody therapeutics’ developer CDR-Life about methods to increase access to antigens and improving immunotherapy treatments. RA: What kind of cancers could benefit from this treatment approach?

Engineering 162

Engineering Clinical Trials Licensing Licensing 162

Drug Target Review

MAY 7, 2024

How do AI-enhanced approaches accelerate the drug development process for rare diseases? AI holds the potential to revolutionise different aspects of healthcare, particularly in the realm of clinical trials. What breakthroughs or advancements do you hope to see in the near future regarding rare disease biomarker research?

Disease 59

Disease Clinical Trials Clinical Pharmacology Trials 59

Conversations in Drug Development Trends

JANUARY 24, 2024

Many parents are hesitant to pursue testing since it will not affect the patient’s care management, as several of these diseases have no approved treatments, such as Fragile X, a syndromic form of autism. As of July 2023, the American Society of Cell + Gene Therapy stated there were 3,905 therapies in development.

Disease 75

Disease Trials Clinical Trials Clinical Research 75

Drug Discovery World

FEBRUARY 12, 2024

Dr Pandora Pound , Fellow Oxford Centre for Animal Ethics explores the hinderances of animal testing in pharma and why new technologies such AI, genomics and synthetic biology c an further drug development. 1 Can this really be regarded as a success?

Animal Testing 147

Animal Testing Disease Trials Research 147

Broad Institute

NOVEMBER 2, 2023

Combining Broad’s expertise in cancer biology and state-of-the-art drug discovery methods with Bayer’s expertise in drug development greatly increases our power to bring transformative medicines to cancer patients.” “We Through this alliance, Broad and Bayer have done just that.

Therapies 105

Therapies Research Small Molecule Clinical Trials 105

KIF1A

SEPTEMBER 30, 2023

Read the Article Both of these studies reflect a global effort to understand the genetic underpinnings of disorders so people can find the right treatments sooner. In addition to benefiting awarded sponsors, this pilot program will help create best practices of communication with the FDA during rare disease therapeutic development.

FDA 111

FDA Disease Clinical Trials Therapies 111

FDA Law Blog: Drug Discovery

JUNE 12, 2024

Sasinowski — Hyman, Phelps & McNamara (HPM) would like to congratulate the 7 rare disease programs selected for the inaugural class of the FDA’s “Support for clinical Trials Advancing Rare disease Treatment” (START) pilot program.

Disease 59

Disease Clinical Trials FDA Clinical Development 59

Cytel

MAY 23, 2024

The use of cloud computing for trial simulation, alongside advances in custom-developed software for this purpose, allow biostatisticians to generate many more design options and to simulate those against a multitude of expected treatment effects to create trials that are more robust against several likely execution scenarios.

Trials 59

Trials Drug Development Treatment Drugs 59

Drug Target Review

MAY 1, 2024

How have advancements in antibody-drug conjugates (ADCs) expanded treatment options for different types of cancer? The advent of monoclonal antibodies paired with improvements in each ADC design component has led to the approval of 11 ADCs with more than 180 ADCs currently in clinical development.

FDA Approval 69

FDA Approval Drugs Organic Chemistry Small Molecule 69

Drug Discovery World

JUNE 1, 2023

Antibody-drug conjugates (ADCs) are biopharmaceutical products in which a monoclonal antibody (mAB) is linked to a small molecule drug with a stable linker 1. According to NCBI, most of the ADCs developed so far are for use in the treatment of cancer, but there is plenty of potential for using ADCs to treat other diseases 1.

Marketing 245

Marketing FDA Approval Licensing Licensing 245

Drug Discovery World

MARCH 7, 2023

She has managed multinational projects for charities and not-for-profits to find new treatments for Malaria and led Innovate UK grants through to successful completion. On the completion of the company’s seed funding, she said: “Whilst life expectancy has increased over recent years, our healthy lifespan has not kept up.

International 246

International Science Pharmaceuticals DNA 246

The Pharma Data

NOVEMBER 3, 2020

Food and Drug Administration (FDA) has granted Fast Track designation to its clinical candidate, LB-001 for the treatment methylmalonic acidemia (MMA). Fast Track designation allows for early and frequent communication with the FDA throughout the entire drug development and review process.

FDA 52

FDA Treatment Clinical Trials Clinical Development 52

Conversations in Drug Development Trends

APRIL 5, 2024

Observed annually on the last day of February since 2008, Rare Disease Day has grown into a global movement for raising awareness, promoting research, and advocating for improved access to rare disease treatments and support services. We were overwhelmed by how excited the community was to participate!

Disease 52

Disease Clinical Trials Trials Treatment 52

The Pharma Data

OCTOBER 26, 2020

Food and Drug Administration (FDA) has granted Fast Track designation for the Company’s experimental gene therapy program, PR001, for the treatment of neuronopathic Gaucher disease (nGD). In addition, the FDA has granted Fast Track designation for PR001 for the treatment of Parkinson’s disease with GBA1 mutations.

FDA 40

FDA Disease Treatment Therapies 40

Drug Discovery World

SEPTEMBER 6, 2022

Advanced therapies are providing new hope for patients and have the potential to revolutionise the way treatments are delivered, and possibly the healthcare landscape as a whole. . Autologous products require customised manufacturing for each patient’s treatment, an expensive and often lengthy process.

Therapies 130

Therapies Clinical Trials Production Disease 130

The Pharma Data

JUNE 25, 2021

Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for lecanemab (BAN2401), an investigational anti-amyloid beta (A?) protofibril antibody for the treatment of Alzheimer’s disease (AD). 1 The proof-of-concept Study 201 explored the impact of treatment with lecanemab on reducing brain amyloid beta (A?)

Disease 40

Disease Treatment Therapies FDA 40

Drug Discovery World

OCTOBER 16, 2023

Indeed, this is bolstered by top tier universities like Newcastle University, which specialises in structure-based approaches for drug discovery, developing innovative technologies that support the identification of new medicines, and is well-established in cancer drug discovery.

Drugs 189

Drugs Science Therapies Targeted Protein Degradation 189

Drug Target Review

JANUARY 8, 2024

We are at the forefront of drug development in an area of research called cellular rejuvenation, which is an approach that has the potential to address many diseases of ageing by restoring aged and injured cells to a more youthful and resilient state. Our lead program utilises OSK for the treatment of age-related optic neuropathies.

Science 145

Science Disease FDA Approval Pharmaceutical Companies 145

LifeSciVC

JULY 11, 2023

Redig, SVP and Head of Clinical Development at HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC The American Cancer Society for Oncology (ASCO) annual meeting is among the highlights of the clinical oncology calendar. By Amanda J. In his presidential address, outgoing ASCO president Dr.

Therapies 67

Therapies Trials Clinical Development Science 67

PerkinElmer

JANUARY 7, 2022

The pharmaceutical industry is under huge pressure to address the high attrition rates in drug development. With around 90% of candidates failing during clinical development, 1 the process is not only long and risky, but also expensive for those involved. References Hingorani, A.D., Sci Rep 9, 18911 (2019).

Drugs 52

Drugs Pharmacokinetics FDA Approval Drug Development 52

The Pharma Data

OCTOBER 25, 2020

Food and Drug Administration (“FDA”) for the treatment of agitation associated with delirium. Treatment choices are limited, and commonly used off-label therapies are not always effective or may result in prolonged, deep sedation. The Company plans to initiate a Phase 2 trial within the next several months. “We

Treatment 52

Treatment Trials FDA Hospitals 52

Alta Sciences

APRIL 17, 2024

Five Promising Treatment Areas in Early-Phase Drug Development in 2024 aasimakopoulos Wed, 04/17/2024 - 15:52 Early-phase drug development is an ever-changing landscape, as emerging science leads to new promising areas of research for the treatment of human health issues.

Drug Development 52

Drug Development Treatment FDA Approval Drugs 52